Szpital Wojewodzki W Opolu Sp. z o.o.

The medical center is at the forefront of research in Chronic Lymphocytic Leukemia, focusing on innovative treatment combinations to improve patient outcomes. The center's studies explore the efficacy of combining targeted therapies with traditional chemotherapy agents.

• Obinutuzumab and Chlorambucil Combination
• Acalabrutinib and Obinutuzumab Combination
• Pirtobrutinib vs. Ibrutinib

These trials aim to enhance progression-free survival and overall response rates, contributing significantly to the evolving landscape of CLL treatment.

Specializing in Polycythemia Vera, the center conducts pivotal research to address the challenges of phlebotomy dependency in patients. By evaluating novel agents, the center seeks to reduce the frequency of phlebotomy, thereby improving quality of life for patients.

• Sapablursen Efficacy and Safety

This research is crucial in developing more effective and less invasive treatment options for PV.

The center is a leader in the study of Diffuse Large B-Cell Lymphoma, focusing on both first-line and consolidation therapies. Research efforts include evaluating the addition of novel agents to standard chemotherapy regimens to improve patient outcomes.

• Acalabrutinib with R-CHOP
• Mosunetuzumab as Consolidation Therapy

These studies aim to enhance treatment efficacy and safety, particularly in elderly or unfit patients, thereby broadening therapeutic options.

In the field of Warm Autoimmune Hemolytic Anemia, the center is dedicated to advancing therapeutic strategies through rigorous clinical trials. The focus is on evaluating the efficacy and safety of novel treatments to manage this complex condition.

• Nipocalimab Efficacy and Safety

These efforts are pivotal in developing new standards of care for patients with wAIHA.

The center is actively engaged in cutting-edge research for Multiple Myeloma, particularly in relapsed or refractory cases. By exploring new therapeutic agents, the center aims to improve treatment efficacy and patient outcomes.

• HDP-101 Safety and Efficacy

This research is instrumental in identifying new treatment paradigms for challenging cases of multiple myeloma.